> Detailanzeige

Miehlke, Stephan; Schneider‐Brachert, Wulf; Kirsch, Christian; Morgner, Andrea; Madisch, Ahmed; Kuhlisch, Eberhard; Haferland, Christian; Bästlein, Elke; Jebens, Claus; Zekorn, Christian; Knoth, Holger; Stolte, Manfred; Lehn, Norbert

One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin
  • Beteiligte: Miehlke, Stephan; Schneider‐Brachert, Wulf; Kirsch, Christian; Morgner, Andrea; Madisch, Ahmed; Kuhlisch, Eberhard; Haferland, Christian; Bästlein, Elke; Jebens, Claus; Zekorn, Christian; Knoth, Holger; Stolte, Manfred; Lehn, Norbert
  • Erschienen: Wiley, 2008
  • Erschienen in: Helicobacter
  • Sprache: Englisch
  • DOI: 10.1111/j.1523-5378.2007.00588.x
  • ISSN: 1083-4389; 1523-5378
  • Schlagwörter: Infectious Diseases ; Gastroenterology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p><jats:bold>Aim: </jats:bold> To investigate a 1‐week once‐daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of <jats:italic>Helicobacter pylori</jats:italic> infection.</jats:p><jats:p><jats:bold>Methods: </jats:bold> Consecutive patients (n = 103) with at least one previous treatment failure and <jats:italic>H. pylori</jats:italic> infection resistant to both metronidazole and clarithromycin were treated with esomeprazole 40 mg, moxifloxacin 400 mg, and rifabutin 300 mg, given once daily for 7 days. Eradication was confirmed by histology and culture. CYP2C19 status was determined by polymerase chain reaction‐restriction fragment length polymorphism.</jats:p><jats:p><jats:bold>Results: </jats:bold> Intention‐to‐treat and per‐protocol eradication rates were 77.7% (68.4–85.3) and 83.3% (74.4–90.2). Five patients discontinued prematurely (4.8%). Eradication was achieved in 93.1% of poor/intermediate metabolizers and in 78.8% of homozygous extensive metabolizers (<jats:italic>p =</jats:italic> .14). Eradication rates in patients with one, two, three, and four or more previous failures were 78.3%, 89.6%, 68.6%, and 88.9%, respectively (<jats:italic>p =</jats:italic> .21). The regimen was effective in seven of nine patients who previously failed quadruple therapy. Post‐treatment resistance to moxifloxacin and rifabutin was detected in two (12.5%) and five (31%) patients after treatment failure.</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> Once‐daily triple therapy with esomeprazole, moxifloxacin, and rifabutin is a promising, safe, and convenient regimen for rescue therapy of <jats:italic>H. pylori </jats:italic>infection that may serve as a valuable alternative to quadruple therapy, particularly for patients with intolerance to amoxicillin.</jats:p>